Itci investor alert: the law offices of vincent wong notifies investors of a class action involving intra-cellular therapies, inc. and a lead plaintiff deadline of july 11, 2017

New york--(business wire)--the law offices of vincent wong announce that a class action lawsuit has been commenced in the usdc for the eastern district of new york on behalf of investors who purchased intra-cellular therapies, inc. ("intra-cellular therapies") (nasdaq:itci) securities between august 12, 2014 and april 28, 2017. click here to learn about the case: http://www.wongesq.com/pslra-sa/intra-cellular-therapies-inc?wire=1. there is no cost or obligation to you. according to the complaint, throughout the class period, the company issued materially false and misleading statements and/or failed to disclose that: (1) findings related to toxicity in animals treated with lumateperone (iti-007) were observed; (2) these findings posed an additional safety concern regarding lumateperone; (2) and as a result of the above, the company’s public statements were materially false and misleading at all relevant times. on august 4, 2016, the company’s ceo sharon mates touted the “efficacy and safety of iti-007 for the treatment of schizophrenia.” then on may 1, 2017, intra-cellular disclosed that the u.s. food and drug administration requested information from the company in order to verify whether or not there are safety risks associated with long term exposure of iti-007 to patients. if you suffered a loss in intra-cellular therapies you have until july 11, 2017 to request that the court appoint you as lead plaintiff. your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. to obtain additional information, contact vincent wong, esq. either via email vw@wongesq.com, by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra-sa/intra-cellular-therapies-inc?wire=1. vincent wong, esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. attorney advertising. prior results do not guarantee similar outcomes.
ITCI Ratings Summary
ITCI Quant Ranking